Home » Newsletters » BioWorld Science

BioWorld Science

Nov. 15, 2010

View Archived Issues

Clinical data indicate RTS,S/AS01E malaria vaccine is safe in infants and children

Phase I/IIa trial evaluates prime-boost vaccination with AdCh63-MSP1 and MVA-MSP1 malaria vaccines

Phase I/II trial shows safety of PfSPZ malaria vaccine in healthy volunteers

Neuraltus Pharma receives grants under QTDP

Pevion Biotech reports preliminary data from phase I PEV-7 trial

Flt3L level in CSF is putative biomarker for primary fibromyalgia and Sjogren's syndrome

Genome-wide meta-analysis suggests involvement of PGC-1-alpha in Parkinson's disease

Wyeth discovers new inhibitors of PI3K-alpha and mTOR

S-47445 to advance to phase I trials for neurogenerative diseases

Eisai claims novel cytidine deaminase inhibitors

Resolve Therapeutics licenses agents for autoimmune disease from University of Washington

Forest Labs and Janssen collaborate on Bystolic and Savella

GlobeImmune receives Federal Therapeutic Discovery Project Program grants

Emergent BioSolutions receives grants for oncology and autoimmunity programs

Pfizer claims new agonists of prostanoid EP2 and EP4 receptors

Infinity Pharma patents new inhibitors of fatty-acid amide hydrolase 1

Oligomerix obtains phase II NIH grant for Alzheimer's disease drug discovery

Ceregene raises funds to further develop CERE-120 and CERE-110

Merck Serono's Saizen recommended for approval in Europe

Cerulean Pharma closes series C financing led by Lilly Ventures

Epeius Biotech gets U.S. federal grant to further develop Rexin-G

Aires Pharma completes series B financing and enters option agreement with Novartis

Santarus launches Cycloset in U.S. to improve glycemic control in type 2 diabetes

Bausch & Lomb begins phase IIb trial of BOL-303259-X for reduction of intraocular pressure

Enrollment complete in phase IIb trial of V-5 immunitor

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 16, 2026.
Precision psychiatry beyond, or before, biomarkers
BioWorld
There is broad agreement that psychiatric diagnoses in their current form are not reflective of any underlying biology, and that this is one of the things...
Keros reports beneficial effects of RKER-065 in ALS model
BioWorld Science
Keros Therapeutics Inc. has presented data regarding their activin receptor ligand trap, RKER-065, for the inhibition of the activin/myostatin signaling axis.
News in brief
BioWorld Asia
BioWorld Asia briefs for March 17, 2026
First-in-class POLG activator restores mtDNA across mutations
BioWorld Science
Researchers from Pretzel Therapeutics Inc. presented preclinical data of PX-578, a first-in-class POLG activator aimed at restoring mtDNA replication and...